FDA Expands Indication for Lutetium-177 PSMA-617 in PSMA-Positive mCRPC
The FDA approved 177Lu PSMA-617 for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer after androgen therapy.
Read More
Transforming Prostate Cancer Care Through Personalized Medicine
Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.
Listen
Extended PSA Monitoring Post-Prostatectomy May Reduce Overtreatment, Study Finds
Investigators found that higher persistent PSA levels after surgery were linked to a worse prognosis, underscoring the importance of timing in post-operative care.
Dizman’s Global Pursuit to Cancer Research and Understanding
In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.
Updated Efficacy Shows Nivolumab Boosts Survival in High-Risk MIBC
During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant nivolumab in patients with bladder cancer.
Analyzing AE Data to Guide Selection of Androgen Receptor Inhibitors in mHSPC
